论文期刊

取消

高级检索

检索历史清除

首页> Gynecologic oncology> Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

导出 OA

翻译打印收藏纠错

作者： Dennis,Mauricio ^[1] ; Stefania,Bellone ^[1] ; Levent,Mutlu ^[1] ; Blair,McNamara ^[1] ; Diego D,Manavella ^[1] ; Cem,Demirkiran ^[1] ; Miguel Skyler Z,Verzosa ^[1] ; Natalia,Buza ^[2] ; Pei,Hui ^[2] ; Tobias Max Philipp,Hartwich ^[1] ; Justin,Harold ^[1] ; Yang,Yang-Hartwich ^[1] ; Margherita,Zipponi ^[1] ; Gary,Altwerger ^[1] ; Elena,Ratner ^[1] ; Gloria S,Huang ^[1] ; Mitchell,Clark ^[1] ; Vaagn,Andikyan ^[1] ; Masoud,Azodi ^[1] ; Peter E,Schwartz ^[1] ; Alessandro D,Santin ^[3]

作者单位： Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America. ^[1] Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States of America. ^[2] Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America. Electronic address: alessandro.santin@yale.edu. ^[3]

关键词 Antibody-drug conjugate DS-8201a HER2/neu Ovarian Carcinosarcoma Trastuzumab deruxtecan Uterine Carcinosarcoma

主题词人类(Humans);女(雌)性(Female);小鼠(Mice);动物(Animals);拓扑异构酶I抑制剂(Topoisomerase I Inhibitors);原位杂交, 荧光(In Situ Hybridization, Fluorescence);细胞系, 肿瘤(Cell Line, Tumor);免疫轭合物(Immunoconjugates);卵巢肿瘤(Ovarian Neoplasms);癌肉瘤(Carcinosarcoma)

DOI 10.1016/j.ygyno.2022.12.018

PMID 36610380

发布时间 2024-03-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Gynecologic oncology

38-45页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷